KIT and chordoma: At the same time, researchers firstly attempted to use imatinib mesylate, a selective tyrosine kinase inhibitor (TKI) of c-KIT and platelet-derived growth factor receptors, for patients with chordoma as it was shown to be highly effective in gastrointestinal stromal tumors (GIST) (51).